Drugs / Rifaximin-α
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07381257 | Jan 2026 → Dec 2027 expected | metabolic dysfunction-associated steatotic liver disease | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02019784 Comparator | Jan 2015 → Jun 2016 | cirrhosis of liver, hepatic encephalopathy | King's College Hospital NHS Trust | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifaximin-α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02019784 ↗ |
| Known as | rifaximin | “Rifaximin is a non-absorbable antibiotic that inhibits urease-producing bacteria and reduces absorption of dietary and bacterial ammonia.” PMID 37467180 ↗ Jul 2023 |
| Action | Inhibit | “inhibits urease-producing bacteria” PMID 37467180 ↗ Jul 2023 |
| Modality | Other / unclassified | “Rifaximin is a non-absorbable antibiotic” PMID 37467180 ↗ Jul 2023 |
| Route | Oral | “Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days” NCT02019784 ↗ |